#49 - 🧃 Juicebox's new T1D toolkit

Hey readers! 👋 This week's been a whirlwind in the T1D world, and we've got a lot to unpack. The Juicebox Podcast dropped some fantastic new resources for both the newly diagnosed and the clinicians who care for them, there's a notable FDA clearance for pregnancy, a new AID system making waves, and some genuinely interesting research updates. Let's dive in! 🧃

The Juicebox Podcast has been busy rolling out content that deserves your attention, whether you're brand new to T1D or have been at this for decades.

Bold Beginnings: Essential Diabetes Insights for the Newly Diagnosed is a new episode from hosts Scott Benner and Jenny Smith (CDE) that focuses on the practical, day-to-day realities of living with T1D rather than textbook theory. - Juicebox Podcast

If you know someone who was recently diagnosed, or if you just want a refresher on fundamentals, Small Sips offers 21 foundational strategies organized across five topics: mindset, insulin, CGM, food, and settings. Each concept is distilled into something you can actually use, which is exactly what people need when they're overwhelmed with new information. - Juicebox Podcast

For the healthcare professionals reading this, the Grand Rounds series continues to be an excellent clinical resource.

The episode lineup covers diagnosis, insulin safety, nutrition, pregnancy, diabetes technology, communication, and long-term management. It's worth sharing with your care team if they haven't discovered it yet. - Juicebox Podcast

FDA Clears Control-IQ+ for Use in Pregnancy With Type 1 Diabetes - This is a significant development for anyone with T1D who is pregnant or planning to be. The FDA has cleared Tandem's Control-IQ+ hybrid closed-loop technology for use during pregnancy with the t:slim X2 and Tandem Mobi pumps paired with a pregnancy-suitable CGM. - HCPLive

In the randomized CIRCUIT trial, Control-IQ+ increased time in the tighter pregnancy target range (63-140 mg/dL) by 12.6%, translating to roughly three additional hours per day in range. Maternal and neonatal outcomes were comparable to standard care. For those who've navigated pregnancy with T1D using manual adjustments, having an FDA-cleared automated option is a meaningful step forward.

Tzield: FDA Expands Immune Therapy Use to Delay Stage III Type 1 Diabetes in Kids as Young as 1 Year Old - The FDA has expanded approval for teplizumab (Tzield) to children as young as one year old with stage II T1D. In a study of 23 children (average age 4.8 years), only two progressed to stage III after the 14-day IV infusion course. - WebMD

This expansion matters because it widens the window for families who catch autoimmunity early through screening programs. The treatment does require careful monitoring for side effects including leukopenia and cytokine-release syndrome, so it's not without trade-offs, but having this option available for very young children is noteworthy.

Discover twiist - Sequel Med Tech's twiist is a next-generation automated insulin delivery system built on the Tidepool Loop algorithm. It delivers insulin adjustments every five minutes, predicts glucose up to six hours ahead, and offers a glucose target range of 87-180 mg/dL. - Sequel Med Tech

What sets twiist apart is its iiSure sound-wave technology, which measures the actual volume of insulin delivered at every dose and detects occlusions up to nine times faster than other systems. It's also the first AID system controllable via iPhone and Apple Watch, which means discreet bolusing from your wrist. The ability to edit carb entries after the fact is a small but genuinely useful quality-of-life feature that anyone who's ever fat-fingered a carb count will appreciate.

SAB-142 lifted time in range to 85% in 4 adults with T1D - Early Phase 1 data from SAB BIO's anti-thymocyte globulin candidate showed all four treated participants preserved C-peptide levels, with mean time-in-range improving from 73% to 85% at Day 120, without increased insulin use. Phase 2b data is expected in late 2027. - Stock Titan

First global gene therapy trial for T1D to start this year - The PROGRESS study will test KRIYA-839, a single intramuscular injection designed to deliver genes for glucokinase and insulin into skeletal muscle. Pre-clinical data showed sustained glucose control for up to four years in animal models. - MedicalBrief

Low-toxicity transplant method reverses T1D in mice - Stanford researchers combined blood stem cell and islet cell transplantation with minimal conditioning, avoiding chronic immunosuppression. Most agents used are already clinically approved, which could speed translation to human trials. - Inside Precision Medicine

Umbilical cord blood may hold clues for T1D risk - Researchers found protein biomarkers in cord blood that predict future T1D risk largely independent of genetics, suggesting environmental factors during pregnancy play a role. As the authors noted: "The biomarkers we identified reflect possibility, not destiny." - The Conversation

That's your week in T1D. Lots happening across technology, research, and practical education. Until next time, take care of yourselves. 💙

Made with ❤️ by Data Drift Press - Hit reply with your questions, comments, or feedback. We love hearing from you!